Using Measurement Strategies to Identify and Monitor Residual Symptoms
Open accessAbstract
Article AbstractMajor depressive disorder (MDD) is a persistent, pervasive, and chronic disorder that significantly affects patients†functioning and quality of life. Most patients treated for MDD continue to have residual symptoms after acute treatment with pharmacotherapy. One of the most commonly encountered residual symptoms is cognitive dysfunction, which substantially affects patient outcomes. While antidepressant monotherapy is an effective first-line treatment for some patients with MDD, patients with residual symptoms (eg, cognitive dysfunction) will require an additional treatment intervention such as augmentation or switch to an alternative treatment strategy. Measurement-based care has been demonstrated to improve patient outcomes in MDD. The clinical importance of cognitive dysfunction in MDD invites the need to probe, screen, and measure the extent of cognitive impairment. (J Clin Psychiatry 2013;74:14-18) From the Department of Psychiatry, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. This article is derived from the planning teleconference series "Depression: Managing the Full Range of Symptoms to Achieve Lasting Remission," which was held in May and June 2013 and supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Lundbeck. Dr McIntyre has served on the advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, France Foundation, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Merck, Organon, Pfizer, and Shire; has served on the speakers bureaus for AstraZeneca, Eli Lilly, Janssen-Ortho, Lundbeck, Merck, and Pfizer; has received grant/research support from AstraZeneca, Eli Lilly, Janssen-Ortho, Lundbeck, the National Alliance for Research on Schizophrenia and Depression, the National Institutes of Mental Health, Pfizer, Shire, and the Stanley Medical Research Institute; and has participated in CME activities for AstraZeneca, Bristol-Myers Squibb, CME Outfitters, Eli Lilly, France Foundation, I3CME, Merck, Optum Health, and Pfizer. Corresponding author: Roger S. McIntyre, MD, 399 Bathurst St, MP 9-325, Toronto, Ontario, M5T 2S8, Canada (roger.mcintyre@uhn.on.ca). doi:10.4088/JCP.12084su1c.03 © Copyright 2013 Physicians Postgraduate Press, Inc.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some authors have advocated for the achievement of 'cognitive remission' as an appropriate, novel aim for major depressive disorder treatment.
“Since cognitive dysfunction is one of the residual symptoms of MDD that most strongly impairs quality of life and since accumulating evidence suggests that persistent cognitive impairment prevents full recovery even following the resolution of depressive episodes, some authors have advocated for the achievement of ‘cognitive remission’ as an appropriate, novel aim for MDD treatment [57, 58].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · see citing works
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139 · see citing works
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · see citing works
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · see citing works
Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study
Spitzer, R. L. (1994) · JAMA · doi:10.1001/jama.272.22.1749 · Cited by 2,648 · see citing works
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177 · see citing works
Utility of a New Procedure for Diagnosing Mental Disorders in Primary Care: The PRIME-MD 1000 Study
Spitzer, R. L. (1994) · JAMA · doi:10.1001/jama.1994.03520220043029 · Cited by 1,873 · see citing works
Ostwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,422 · see citing works
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292 · see citing works
Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (2013) · PsycTESTS Dataset · doi:10.1037/t03589-000 · Cited by 946 · see citing works
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765 · see citing works
Self-citationZung, W. W. K. (1965) · PsycTESTS Dataset · doi:10.1037/t04095-000 · Cited by 636 · see citing works
Frasure-Smith, N., & Lespérance, F. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.4 · Cited by 571 · see citing works
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552 · see citing works
Conradi, H. J., Ormel, J., & de Jonge, P. (2011) · Psychological Medicine · doi:10.1017/s0033291710001911 · Cited by 515 · see citing works
Cognitive functioning in major depression – a summary
Hammar, Å. (2009) · Frontiers in Human Neuroscience · doi:10.3389/neuro.09.026.2009 · Cited by 491 · see citing works
Neurocognitive deficits and disability in major depressive disorder
Jaeger, J., Berns, S., Uzelac, S., & Davis-Conway, S. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.11.011 · Cited by 484 · see citing works
Judd, L. L., Paulus, M. J., Schettler, P. J., Akiskal, H. S., Endicott, J., Leon, A. C., Maser, J. D., Mueller, T., Solomon, D. A., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1501 · Cited by 458 · see citing works
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · see citing works
Papakostas, G. I., & D, M. F. M. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.009 · Cited by 381 · see citing works
Keilp, J. G., Gorlyn, M., Russell, M., Oquendo, M. A., Burke, A. K., Harkavy-Friedman, J., & Mann, J. J. (2013) · Psychological Medicine · doi:10.1017/s0033291712001419 · Cited by 350 · see citing works
Raskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.164.6.900 · Cited by 336 · see citing works
Self-Rated Global Measure of the Frequency, Intensity, and Burden of Side Effects
Wisniewski, S. R., Rush, A. J., Balasubramani, G. K., Trivedi, M. H., & Nierenberg, A. A. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200603000-00002 · Cited by 288 · see citing works
Gorwood, P. A. P. M., Corruble, E., Falissard, B., & Goodwin, G. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07040574 · Cited by 254 · see citing works
Erickson, K., Drevets, W. C., Clark, L., Cannon, D. M., Bain, E. E., Zarate, C. A., Charney, D. S., & Sahakian, B. J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2171 · Cited by 203 · see citing works
Long‐term social functioning after depression treated by psychiatrists: a review
Kennedy, N., Foy, K. C., Sherazi, R., McDonough, M., & McKeon, P. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00326.x · Cited by 191 · see citing works
Naismith, S. L., Longley, W. A., Scott, E. M., & Hickie, I. B. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-32 · Cited by 146 · see citing works
Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale
McIntyre, R. S. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050786 · Cited by 142 · see citing works
Self-citationTrivedi, M. H., & Daly, E. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.01.007 · Cited by 112 · see citing works
Bostanov, V., Keune, P. M., Kotchoubey, B., & Hautzinger, M. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.05.031 · Cited by 70 · see citing works
Gelenberg, A. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9058se1c.01gry · Cited by 54 · see citing works
Ketamine for the Treatment of Depression
Howland, R. H. (2013) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20121219-01 · Cited by 43 · see citing works
Adherence to Treatment for Geriatric Depression and Anxiety
Wetherell, J. L., & Unützer, J. (2003) · CNS Spectrums · doi:10.1017/s1092852900008270 · Cited by 32 · see citing works
Ballenger, J. C. (2011) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(10)79300-2 · Cited by 28 · see citing works
Using a Self-Report Depression Scale to Identify Remission in Depressed Outpatients
Zimmerman, M. A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.10.1911 · Cited by 21 · see citing works
Trivedi, M. H., Greer, T. L., Church, T. S., et al. (2011) · Scholar Commons (University of South Carolina) · Cited by 15 · see citing works
Flagged first, then by citations
Research works printed but not linked: 16
- Luppa M, Heinrich S, Angermeyer MC, et al. Cost-of-illness studies of depression: a systematic review. J Affect Disord. 2007;98(1-2):29-43. d o i : 1 0 . 1 0 1 6 / j . j a d . 2 0 0 6 . 0 7 . 0 1
- P u b M e d 6. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292. d o i : 1 0 . 1 0 9 7 / 0 1 · DOI
- 3 C P u b M e d 7. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. d o i : 1 0 . 1 0 4 6 / j . 1 5 2 5 -1 4 9 7 . 2 0 0 1 . 0 1 6 0 0 9 6
- P u b M e d 10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
- First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; November, 2002.
- Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23(8):627-647.
- Tranter R, O'Donovan C, Chandarana P, et al. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci. 2002;27(4):241-247.
- P u b M e d 20. Stotland NL. Recovery from depression. Psychiatr Clin North Am. 2012;35(1):37-49. d o i : 1 0 . 1 0 1 6 / j . p s c . 2 0 1 1 . 1 1 . 0 0
- Qaseem A, Snow V, Denberg TD, et al, for the Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149(10):725-733. d o i : 1 0 . 7 3 2 6 / 0 0 0 3 -4 8 1 9 -1 4 9 -1 0 -2 0 0 8 1 1 1 8 0 -0 0 0 0
- Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167(8):942-948. d o i : 1 0 . 1 1 7 6 / a p p i . a j p . 2 0 0 9 . 0 9 0 8 1 1 9
- P u b M e d 40. Papakostas GI, Shelton RC, Zajecka JM, et al. l-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel- sequential trials. Am J Psychiatry. 2012;169(12):1267-1274. d o i : 1 0 . 1 1 7 6 / a p p i . a j p . 2 0 1 2 . 1 1 0 7 1 1 1
- Radloff LS. The CES-D Scale: a self-report depression scale for research in the 2. general population. Appl Psychol Meas. 1977;1(3):385-401.
- Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: 4. validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292.
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression 5. severity measure. J Gen Intern Med. 2001;16(9):606-613.
- Zimmerman M, Mattia JI. A self-report scale to help make psychiatric 9. diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Arch Gen Psychiatry. 2001;58(8):787-794.
- Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of 17. Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self- Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583.
Cited by
Sorted by citations
<p>Cognitive impairment in depression: recent advances and novel treatments</p>
Perini, G., Cotta Ramusino, M., Sinforiani, E., Bernini, S., Petrachi, R., & Costa, A. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199746 · Cited by 384 · see citing works
Cognitive remission: a novel objective for the treatment of major depression?
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016) · BMC Medicine · doi:10.1186/s12916-016-0560-3 · Cited by 252 · see citing works
Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review
Bortolato, B., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203823 · Cited by 181 · see citing works
Self-citationCognition as a target in major depression: new developments.
Solé, B., Jiménez, E., Martinez-Aran, A., & Vieta, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.004 · Cited by 68 · see citing works
- Authors
- McIntyre, R. S.
- Affiliations
- University Health Network (CA)
- Corresponding author
- McIntyre, Roger S.
- ORCID
- McIntyre, Roger S.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2013-10
- Volume
- 74
- Issue
- suppl 2
- Pages
- 14-18
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1978278516
- Cited by
- 25
- References
- 36
- Citations by year
- 2025: 1 · 2023: 3 · 2022: 3 · 2020: 1 · 2019: 2 · 2018: 4 · 2016: 4 · 2015: 6 · 2014: 1
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Stanley Medical Research Institute
- National Alliance for Research on Schizophrenia and Depression
- H. Lundbeck A/S
- Takeda Pharmaceuticals International
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Mental Health Research Topics
- Keywords
- major depressive disorder, residual symptoms, cognitive impairment, measurement-based care, antidepressant augmentation, antidepressant switching, cognitive screening, treatment response monitoring, remission, pharmacotherapy, quality of life, patient functioning, relapse prevention
- MeSH terms
- Cognition Disorders, Depressive Disorder, Major, Major Depressive Disorder, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
